Adenovirus (Ad) infections are usually mild and self-limiting, but severe systemic infections and fatal diseases can occur, especially in immunosuppressed patients. Anti-adenoviral pharmacotherapy has been proven to inhibit Ad infection, but its efficiency is limited. This review addresses biological antiviral agents as a new class of therapeutics for treatment of Ad infections. One group of agents is composed of short double-stranded RNA molecules that have been developed to inhibit Ad receptor and Ad protein expression. The second group of agents includes soluble virus receptor traps which inhibit Ad uptake into cells. Anti-Ad-adoptive T-cell therapy constitutes a third approach. We also outline how the combination of biological antiviral agents and combinations of these agents with the classical antiviral drugs can increase therapeutic efficiency in anti-adenoviral treatments.
References
1.
FreimüllerC., StembergerJ., ArtwohlM.Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.Cytotherapy2015; 17: 989–1007.
2.
WallsT., ShankarA.G., ShingadiaD.Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients.Lancet Infect Dis2003; 3: 79–86.
3.
SmithJ.G., WiethoffC.M., StewartP.L., NemerowG.R.Adenovirus.Curr Top Microbiol Immunol2010; 343: 195–224.
4.
RussellW.C.Update on adenovirus and its vectors.J Gen Virol2000; 81: 2573–2604.
5.
EchavarríaM.Adenoviruses in immunocompromised hosts.Clin Microbiol Rev2008; 21: 704–715.
6.
HongJ.Y., LeeH.J., PiedraP.A.Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis.Clin Infect Dis2001; 32: 1423–1429.
7.
ZhangS.Y., LuoY.P., HuangD.D.Fatal pneumonia cases caused by human adenovirus 55 in immunocompetent adults.Infect Dis (Lond)2016; 48: 40–47.
8.
FlorescuD.F., PergamS.A., NeelyM.N.Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.Biol Blood Marrow Transplant2012; 18: 731–738.
9.
LionT., BaumgartingerR., WatzingerF.Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease.Blood2003; 102: 1114–1120.
10.
KampmannB., CubittD., WallsT.Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation.Br J Haematol2005; 130: 595–603.
11.
GanzenmuellerT., BuchholzS., HarsteG., DammannE., TrenschelR., HeimA.High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load.J Clin Virol2011; 52: 55–59.
12.
SiveJ.I., ThomsonK.J., MorrisE.C., WardK.N., PeggsK.S.Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults.Clin Infect Dis2012; 55: 1362–1370.
KajonA.E., DicksonL.M., FisherB.T., HodinkaR.L.Fatal disseminated adenovirus infection in a young adult with systemic lupus erythematosus.J Clin Virol2011; 50: 80–83.
19.
SchilhamM.W., ClaasE.C., van ZaaneW.High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation.Clin Infect Dis2002; 35: 526–532.
20.
VyasJ.M., MarascoW.A.Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients.Case Rep Infect Dis2012; 2012: 463569.
21.
KojaoghlanianT., FlomenbergP., HorwitzM.S.The impact of adenovirus infection on the immunocompromised host.Rev Med Virol2003; 13: 155–171.
22.
WallotM.A., Dohna-SchwakeC., AuthM.Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide.Pediatr Transplant2006; 10: 121–127.
23.
ParasuramanR., ZhangP.L., SamarapungavanD., RocherL., KoffronA.Severe necrotizing adenovirus tubulointerstitial nephritis in a kidney transplant recipient.Case Rep Transplant2013; 2013: 969186.
24.
ChakrabartiS., MautnerV., OsmanH.Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery.Blood2002; 100: 1619–1627.
WoldW.S., TothK.New drug on the horizon for treating adenovirus.Expert Opin Pharmacother2015; 16: 2095–2099.
27.
CihlarT., ChenM.S.Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells.Mol Pharmacol1996; 50: 1502–1510.
28.
De ClercqE., HolyA.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Nat Rev Drug Discov2005; 4: 928–940.
29.
LjungmanP., RibaudP., EyrichM.Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant2003; 31: 481–486.
30.
TaniguchiK., YoshiharaS., TamakiH.Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation.Ann Hematol2012; 91: 1305–1312.
31.
BhadriV.A., Lee-HornL., ShawP.J.Safety and tolerability of cidofovir in high-risk pediatric patients.Transpl Infect Dis2009; 11: 373–379.
32.
HostetlerK Y.. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate.Viruses2010; 2: 2213–2225.
33.
PaolinoK., SandeJ., PerezE.Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001.J Clin Virol2011; 50: 167–170.
34.
AwosikaO.O., LyonsJ.L., CiarliniP.Fatal adenovirus encephalomyeloradiculitis in an umbilical cord stem cell transplant recipient.Neurology2013; 80: 1715–1717.
35.
KeyesA., MathiasM., BouladF.Cutaneous involvement of disseminated adenovirus infection in an allogeneic stem cell transplant recipient.Br J Dermatol2016; 174: 885–888.
36.
KurreckJ.RNA interference: from basic research to therapeutic applications.Angew Chem Int Ed Engl2009; 48: 1378–1398.
37.
BobbinM.L., BurnettJ.C., RossiJ.J.RNA interference approaches for treatment of HIV-1 infection.Genome Med2015; 7: 50.
38.
DallasA., IlvesH., MaH.Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy.J Virol2014; 88: 4647–4656.
39.
XuF., LiuG., LiuQ., ZhouY.RNA interference of influenza A virus replication by microRNA-adapted lentiviral loop short hairpin RNA.J Gen Virol2015; 96: 2971–2981.
NevinsJ.R., RaychaudhuriP., YeeA.S., RooneyR.J., KovesdiI., ReichelR.Transactivation by the adenovirus E1A gene.Biochem Cell Biol1988; 66: 578–583.
42.
GrandR.J., IbrahimA.P., TaylorA.M.Human cells arrest in S phase in response to adenovirus 12 E1A.Virology1998; 244: 330–342.
43.
EcksteinA., GrosslT., GeislerA.Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions.Antiviral Res2010; 88: 86–94.
44.
BackströmE., KaufmannK.B., LanX., AkusjarviG.Adenovirus L4-22K stimulates major late transcription by a mechanism requiring the intragenic late-specific transcription factor-binding site.Virus Res2010; 151: 220–228.
45.
ZhangW., ImperialeM.J.Requirement of the adenovirus IVa2 protein for virus assembly.J Virol2003; 77: 3586–3594.
46.
TylerR.E., EwingS.G., ImperialeM.J.Formation of a multiple protein complex on the adenovirus packaging sequence by the IVa2 protein.J Virol2007; 81: 3447–3454.
47.
HittM.M., GrahamF.L.Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication.Virology1990; 179: 667–678.
48.
KneidingerD., IbrisimovicM., LionT., KleinR.Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery.Antiviral Res2012; 94: 195–207.
49.
ScomparinA., PolyakD., KrivitskyA., Satchi-FainaroR.Achieving successful delivery of oligonucleotides - from physico-chemical characterization to in vivo evaluation.Biotechnol Adv2015; 33: 1294–1309.
50.
NikitenkoN.A., SpeisederT., LamE.Regulation of human adenovirus replication by RNA interference.Acta Naturae2015; 7: 100–107.
51.
GrimmD., StreetzK.L., JoplingC.L.Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.Nature2006; 441: 537–541.
52.
GrößlT., HammerE., Bien-MollerS.A novel artificial microRNA expressing A AV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum.PLoS ONE2014; 9: e92188.
53.
BoudreauR.L., MartinsI., DavidsonB.L.Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.Mol Ther2009; 17: 169–175.
54.
IbrisimovicM., KneidingerD., LionT., KleinR.An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs.Antiviral Res2013; 97: 10–23.
55.
FechnerH., WangX., WangH.Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells.Gene Ther2000; 7: 1954–1968.
56.
WerkD., SchubertS., LindigV.Developing an effective RNA interference strategy against a plus-strand RNA virus: silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor.Biol Chem2005; 386: 857–863.
57.
FechnerH., PinkertS., WangX.Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor.Gene Ther2007; 14: 960–971.
58.
AlemanyR., CurielD.T.CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.Gene Ther2001; 8: 1347–1353.
59.
YunC.O., YoonA.R., YooJ.Y.Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity.Hum Gene Ther2005; 16: 248–261.
60.
RoelvinkP.W., LizonovaA., LeeJ.G.The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F.J Virol1998; 72: 7909–7915.
61.
SegermanA., AtkinsonJ.P., MarttilaM., DennerquistV., WadellG., ArnbergN.Adenovirus type 11 uses CD46 as a cellular receptor.J Virol2003; 77: 9183–9191.
62.
FischerR., PollerW., SchultheissH.P., GotthardtM.CAR-diology–a virus receptor in the healthy and diseased heart.J Mol Med (Berl)2009; 87: 879–884.
63.
FechnerH., PinkertS., GeislerA., PollerW., KurreckJ.Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.Molecules2011; 16: 8475–8503.
64.
SilbersteinE., KonduruK., KaplanG.G.The interaction of hepatitis A virus (HAV) with soluble forms of its cellular receptor 1 (HAVCR1) share the physiological requirements of infectivity in cell culture.Virol J2009; 6: 175.
BergelsonJ.M., CunninghamJ.A., DroguettG.Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.Science1997; 275: 1320–1323.
67.
TomkoR.P., JohanssonC.B., TotrovM., AbagyanR., FrisenJ., PhilipsonL.Expression of the adenovirus receptor and its interaction with the fiber knob.Exp Cell Res2000; 255: 47–55.
68.
ExcoffonK.J., TraverG.L., ZabnerJ.The role of the extracellular domain in the biology of the coxsackievirus and adenovirus receptor.Am J Respir Cell Mol Biol2005; 32: 498–503.
69.
YanagawaB., SpillerO.B., ProctorD.G.Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.J Infect Dis2004; 189: 1431–1439.
70.
HarrisC.L., WilliamsA.S., LintonS.M., MorganB.P.Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.Clin Exp Immunol2002; 129: 198–207.
71.
MarchantD., SiX., LuoH., McManusB., YangD.The impact of CVB3 infection on host cell biology.Curr Top Microbiol Immunol2008; 323: 177–198.
72.
KarnauchowT.M., TolsonD.L., HarrisonB.A., AltmanE., LublinD.M., DimockK.The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55).J Virol1996; 70: 5143–5152.
73.
ShafrenD.R., BatesR.C., AgrezM.V., HerdR.L., BurnsG.F., BarryR.D.Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment.J Virol1995; 69: 3873–3877.
74.
HafensteinS., BowmanV.D., ChipmanP.R.Interaction of decay-accelerating factor with coxsackievirus B3.J Virol2007; 81: 12927–12935.
75.
RögerC., PozzutoT., KlopfleischR., KurreckJ., PinkertS., FechnerH.Expression of an engineered soluble coxsackievirus and adenovirus receptor by a dimeric AAV9 vector inhibits adenovirus infection in mice.Gene Ther2015; 22: 458–466.
76.
WaddingtonS.N., ParkerA.L., HavengaM.Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5.J Virol2007; 81: 9568–9571.
77.
AlbaR., BradshawA.C., ParkerA.L.Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.Blood2009; 114: 965–971.
78.
LiM., LiH., RossiJ.J.RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.Ann N Y Acad Sci2006; 1082: 172–179.
79.
HeemskerkB., LankesterA.C., van VreeswijkT.Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients.J Infect Dis2005; 191: 520–530.
80.
MaC.K., BlythE., ClancyL.Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.Cytotherapy2015; 17: 1406–1420.
81.
PapadopoulouA., GerdemannU., KatariU.L.Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.Sci Transl Med2014; 6: 242ra83.
82.
FeuchtingerT., Matthes-MartinS., RichardC.Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.Br J Haematol2006; 134: 64–76.
83.
LeenA.M., BollardC.M., MendizabalA.M.Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.Blood2013; 121: 5113–5123.
84.
SiliU., LeenA.M., VeraJ.F.Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.Cytotherapy2012; 14: 7–11.
85.
GerdemannU., KatariU.L., PapadopoulouA.Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.Mol Ther2013; 21: 2113–2121.
86.
LiM., LiH., RossiJ.J.RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.Ann N Y Acad Sci2006; 1082: 172–179.
87.
ParkJ.G., ParkS.Y.Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.Clin Mol Hepatol2015; 21: 242–248.
88.
SawinskiD., KaurN., AjetiA.Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents.Am J Transplant2016; 16: 1588–1595.
89.
DeloryT., PapotE., RiouxC.Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: a case-series experience.J Med Virol2016; 88: 1204–1210.
90.
PozzutoT., RögerC., KurreckJ., FechnerH.Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir.Antiviral Res2015; 120: 72–78.
